Browse the evidence

Higher sodium intake is associated with an increased risk of stroke, stroke mortality, and coronary heart disease mortality in adults.

While direct mortality data from trials is limited, observational evidence suggests that high sodium intake increases the risk of stroke and heart disease death. Maintaining moderate sodium levels supports long-term cardiovascular health.

In young obese subjects, lower fecal Escherichia coli abundance is associated with higher serum lipopolysaccharide (LPS) levels, indicating that reduced E. coli may increase the risk of metabolic endotoxemia.

If you are obese, having very low levels of E. coli in your gut might actually be a risk factor for metabolic issues like inflammation, rather than a benefit. This suggests that simply trying to eliminate all bacteria is not the right approach; maintaining a balanced microbiome is key.

Higher serum lipopolysaccharide (LPS) levels in obese young subjects are positively correlated with BMI, waist circumference, and triglyceride levels, linking metabolic endotoxemia to central adiposity.

For young obese individuals, higher levels of gut-derived toxins (LPS) in the blood are linked to higher body weight, larger waist size, and higher triglycerides. This suggests that gut health plays a role in metabolic health beyond just calories.

Exercise-induced myokines, including IL-6, IL-15, and FSTL1, mediate muscle-bone, muscle-skin, and muscle-vascular crosstalk, promoting bone formation, skin health, and cardiovascular protection.

Regular exercise helps maintain strong bones and healthy skin by triggering your muscles to release factors like IGF-1 and IL-15. These signals support bone formation and skin structure, contributing to overall long-term health and vitality.

Elevated gut-derived SCFA production contributes to metabolic health by modulating appetite, energy expenditure, and glucose homeostasis.

Incorporate prebiotic fibers (like inulin, resistant starch, and GOS) into your diet to naturally boost SCFA production. This may help regulate appetite and blood sugar. However, do not expect immediate metabolic fixes; this is a long-term strategy supported by strong mechanistic data but requiring more robust human trials.

Daily oral administration of live Akkermansia muciniphila (2.10^8 cells) improves metabolic health in high-fat diet-fed mice by restoring gut barrier function and reducing metabolic endotoxemia.

While human trials are ongoing, current research suggests that consuming Akkermansia muciniphila (specifically pasteurized forms which are more stable and effective) may help improve metabolic health by strengthening the gut barrier. It is not just about 'live' bacteria; the structural components of the bacteria are key.

Pasteurization of Akkermansia muciniphila enhances its metabolic benefits compared to live administration, likely due to the exposure of outer membrane proteins like Amuc_1100.

If you take Akkermansia muciniphila, a pasteurized (heat-treated) version may be more effective than a live one. The heat process exposes specific proteins (Amuc_1100) that boost metabolic health. This form is also more stable for storage.

The contribution of nitric oxide to exercise hyperaemia (blood flow increase during exercise) is significant (20-30%) but not obligatory, with redundancy in vasodilator mechanisms allowing other pathways to compensate.

While nitric oxide helps increase blood flow during exercise, your body has backup systems (like prostaglandins) that ensure blood flow increases even if NO is blocked. This means you don't need to worry about 'blocking' NO to get benefits; the body adapts.

Selective insulin resistance occurs in the liver where insulin fails to suppress hepatic glucose production (gluconeogenesis) but continues to stimulate lipogenesis (fat creation), leading to hyperglycemia and hepatic steatosis.

Standard insulin therapy may not fix high blood sugar in liver disease because the liver's fat-making machinery is still overactive. Treatments need to target both glucose production and fat synthesis.

Ketogenic diets show promise as an adjunctive therapy for cancer, potentially reducing tumor progression through glucose 'starvation' and reduced insulin/IGF-1 signaling, though evidence is currently preliminary.

For cancer patients, a VLCKD may be a promising adjunctive therapy by reducing glucose and insulin levels, potentially slowing tumor growth, but it should only be considered under medical supervision as evidence is still preliminary.

NAMPT (Nicotinamide Phosphoribosyltransferase) is the rate-limiting enzyme in the NAD+ salvage pathway and serves as a critical link between circadian rhythms and metabolism.

Your body's ability to produce NAD+ is regulated by a key enzyme called NAMPT, which follows a daily (circadian) rhythm. Eating at consistent times and maintaining a regular sleep-wake cycle may support this enzyme's function, thereby supporting your metabolic health.

Increased secretion of GLP-1 induced by delivering nutrients to lower parts of the small intestines explains weight loss and improvements in glycaemic control after bariatric surgery.

Bariatric surgery, such as Roux-en-Y gastric bypass, improves metabolic control partly by increasing GLP-1 secretion from the lower small intestine. This hormonal change contributes to weight loss and better blood sugar control.

Melatonin exhibits oncostatic properties by inhibiting tumor growth in estrogen-positive breast cancer and other tumors, potentially by modulating estrogen signaling and fatty acid uptake.

Melatonin may help inhibit tumor growth in estrogen-positive cancers, but it is not a standalone cure. Night shift workers may have higher cancer risk due to suppressed melatonin.

Activation of AMP-activated protein kinase (AMPK) inhibits NF-κB signaling and suppresses chronic inflammation, thereby improving healthspan and extending lifespan.

To leverage AMPK for longevity and inflammation control, prioritize physical exercise and dietary strategies that naturally activate this pathway, such as consuming phytochemicals (e.g., resveratrol, curcumin) and maintaining energy balance. These lifestyle factors are known physiological inducers of AMPK, which in turn suppresses inflammatory signaling linked to aging and metabolic disease.

Administration of the bacterium Akkermansia muciniphila reverses hyperglycemia and reduces body weight in murine models of obesity and type 2 diabetes.

While A. muciniphila shows promise in mice for reversing diabetes and obesity, human results are mixed. Focus on prebiotics like oligofructose, which naturally increase A. muciniphila levels and have shown metabolic benefits in humans, rather than seeking unproven bacterial supplements.

Metformin treatment increases the abundance of Akkermansia muciniphila, contributing to its metabolic benefits.

If you take Metformin for Type 2 Diabetes, it may be helping your gut health by increasing Akkermansia muciniphila. This is one of the mechanisms by which the drug improves metabolic function.

Muscle fiber loss (hypoplasia) and motor unit denervation contribute significantly to age-related muscle atrophy, independent of simple fiber shrinking.

Maintaining muscle isn't just about eating protein; it's about keeping the nerve connections to your muscles intact. Regular resistance exercise is crucial to stimulate these nerves and prevent the actual loss of muscle fibers.

The PPARγ Pro12Ala polymorphism is associated with a modestly increased risk of type 2 diabetes, but its effect on insulin sensitivity is likely mediated through changes in body mass index (BMI) and adiposity rather than direct metabolic effects.

Carrying the Pro12Ala variant slightly increases diabetes risk, mostly by influencing body weight. Maintaining a healthy BMI is the most effective way to mitigate this genetic risk.

TNF-α and IL-6 are pro-inflammatory adipokines that contribute to insulin resistance by interfering with insulin signaling pathways, such as through JNK1-mediated serine phosphorylation of IRS-1.

Chronic low-grade inflammation from fat tissue releases TNF-α and IL-6, which can interfere with how insulin signals cells. While this is a key mechanism in animals, simply blocking these markers in humans has not consistently worked, suggesting a more complex interplay.

Exposure to environmental organotins (specifically tributyltin and triphenyltin) acts as an obesogen by functioning as nanomolar agonist ligands for nuclear receptors RXR and PPAR-gamma, thereby inappropriately driving adipocyte differentiation and increasing fat mass.

While you cannot easily control all environmental exposures, being aware that certain chemicals (like those in some plastics or treated wood) may influence fat storage biology can motivate reducing exposure where possible (e.g., avoiding plastic containers for hot foods, choosing untreated wood). However, this does not replace the fundamental importance of diet and exercise.

Treatment of NAFLD with specific pharmacological agents, particularly pioglitazone and GLP-1 receptor agonists, can improve liver histology and potentially reduce cardiovascular risk, although large RCTs focusing on CVD outcomes are still needed.

If lifestyle changes are insufficient, medications like pioglitazone or GLP-1 agonists may be considered. They have shown efficacy in improving liver inflammation and fibrosis in clinical trials. Discuss with your doctor if these are appropriate for your cardiovascular risk profile.

Activation of AgRP neurons by UDP (uridine-diphosphate) promotes feeding and weight gain, and elevated circulating uridine levels in obesity may sustain this vicious cycle.

This is a basic science finding; no direct human intervention is currently recommended based on this specific pathway alone.

Activation of SIRT1, SIRT3, and SIRT6 improves glucose metabolism and insulin sensitivity through mechanisms involving AMPK activation, NF-kB inhibition, and regulation of transcription factors like FoxO1 and PGC1α.

While specific SIRT-activating supplements are marketed, the most reliable way to support SIRT activity and metabolic health is through exercise and maintaining metabolic balance. The paper highlights that exercise improves SIRT6-mediated insulin signaling and that SIRT1 activation via AMPK helps glucose tolerance. Focus on consistent physical activity and metabolic health rather than unproven supplements.

SIRTs (particularly SIRT1, SIRT2, SIRT6, and SIRT7) exert anti-inflammatory effects by inhibiting the NF-kB pathway and reducing pro-inflammatory cytokines like TNF-alpha and IL-6.

Chronic inflammation is a risk factor for many diseases. SIRTs help regulate this process. While specific SIRT activators are not yet standard therapy, lifestyle factors that support SIRT activity (like exercise) may help manage inflammatory markers naturally.